192 related articles for article (PubMed ID: 9408960)
1. Pharmacologic approaches to reversing multidrug resistance.
Sikic BI
Semin Hematol; 1997 Oct; 34(4 Suppl 5):40-7. PubMed ID: 9408960
[TBL] [Abstract][Full Text] [Related]
2. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
3. Clinical studies with modulators of multidrug resistance.
Fisher GA; Sikic BI
Hematol Oncol Clin North Am; 1995 Apr; 9(2):363-82. PubMed ID: 7642468
[TBL] [Abstract][Full Text] [Related]
4. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
5. [SDZ PSC 833: a novel modulator of MDR].
Covelli A
Tumori; 1997; 83(5 Suppl):S21-4. PubMed ID: 9446255
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance in multiple myeloma.
Sonneveld P; Lokhorst HM; Vossebeld P
Semin Hematol; 1997 Oct; 34(4 Suppl 5):34-9. PubMed ID: 9408959
[TBL] [Abstract][Full Text] [Related]
7. Modulation of multidrug resistance: a paradigm for translational clinical research.
Sikic BI
Oncology (Williston Park); 1999 May; 13(5A):183-7. PubMed ID: 10370927
[TBL] [Abstract][Full Text] [Related]
8. PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance.
Atadja P; Watanabe T; Xu H; Cohen D
Cancer Metastasis Rev; 1998 Jun; 17(2):163-8. PubMed ID: 9770112
[TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
[TBL] [Abstract][Full Text] [Related]
10. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.
Lum BL; Gosland MP
Hematol Oncol Clin North Am; 1995 Apr; 9(2):319-36. PubMed ID: 7642466
[TBL] [Abstract][Full Text] [Related]
11. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
12. Modulators of multidrug resistance. Preclinical studies.
Ford JM
Hematol Oncol Clin North Am; 1995 Apr; 9(2):337-61. PubMed ID: 7642467
[TBL] [Abstract][Full Text] [Related]
13. Modulation of multidrug resistance (MDR) in hematological malignancies.
Covelli A
Ann Oncol; 1999; 10 Suppl 6():53-9. PubMed ID: 10676553
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
15. Overcoming multidrug resistance: valspodar as a paradigm for nursing care.
Berg D; Centrilla L; Halsey J; Silvester P; Jones B; Guynn K; Mayer DK
Oncol Nurs Forum; 1999 May; 26(4):711-20. PubMed ID: 10337649
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein.
Archinal-Mattheis A; Rzepka RW; Watanabe T; Kokubu N; Itoh Y; Combates NJ; Bair KW; Cohen D
Oncol Res; 1995; 7(12):603-10. PubMed ID: 8704277
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms.
Li X; Li JP; Yuan HY; Gao X; Qu XJ; Xu WF; Tang W
Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):607-17. PubMed ID: 18193112
[TBL] [Abstract][Full Text] [Related]
19. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
20. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
Nobili S; Landini I; Mazzei T; Mini E
Med Res Rev; 2012 Nov; 32(6):1220-62. PubMed ID: 21374643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
